{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:15Z","timestamp":1740106935141,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Beijing Medical and Health Foundation","award":["No.2221-16-157"],"award-info":[{"award-number":["No.2221-16-157"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00277-019-03812-w","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T05:14:29Z","timestamp":1579842869000},"page":"549-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory\/relapsed classical Hodgkin lymphoma: a single center experience from China"],"prefix":"10.1007","volume":"99","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Ju","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"issue":"12","key":"3812_CR1","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 128(12):1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","journal-title":"Blood."},{"issue":"19","key":"3812_CR2","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, KEYNOTE-087 (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72","journal-title":"J Clin Oncol"},{"issue":"14","key":"3812_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 36(14):1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"issue":"9323","key":"3812_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M\u00fcller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, German Hodgkin's Lymphoma Study Group, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 359(9323):2065\u20132071","journal-title":"Lancet."},{"issue":"8852","key":"3812_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 341(8852):1051\u20131054","journal-title":"Lancet."},{"issue":"2","key":"3812_CR6","first-page":"467","volume":"20","author":"C Ferm\u00e9","year":"2002","unstructured":"Ferm\u00e9 C, Mounier N, Divin\u00e9 M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin\u2019s disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20(2):467\u2013475","journal-title":"J Clin Oncol"},{"issue":"5","key":"3812_CR7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","volume":"97","author":"A Rimner","year":"2017","unstructured":"Rimner A, Lovie S, Hsu M, Chelius M, Zhang Z, Chau K, Moskowitz AJ, Matasar M, Moskowitz CH, Yahalom J (2017) Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience. Int J Radiat Oncol Biol Phys 97(5):1066\u20131076. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.01.222","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"3812_CR8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the\u2002Lugano\u2002classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"1","key":"3812_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/10428194.2013.802784","volume":"55","author":"M Meignan","year":"2014","unstructured":"Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A (2014) Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held inMenton, France, 3-5 October 2012. Leuk Lymphoma 55(1):31\u201337. https:\/\/doi.org\/10.3109\/10428194.2013.802784","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"3812_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","volume":"131","author":"SH Lim","year":"2018","unstructured":"Lim SH, Johnson PWM (2018) Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 131(15):1679\u20131688. https:\/\/doi.org\/10.1182\/blood-2017-09-772640","journal-title":"Blood."},{"issue":"15","key":"3812_CR11","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","volume":"131","author":"PJ Br\u00f6ckelmann","year":"2018","unstructured":"Br\u00f6ckelmann PJ, Sasse S, Engert A (2018) Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 131(15):1666\u20131678. https:\/\/doi.org\/10.1182\/blood-2017-10-772665","journal-title":"Blood."},{"issue":"8","key":"3812_CR12","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/10428194.2017.1403601","volume":"59","author":"L Giulino-Roth","year":"2018","unstructured":"Giulino-Roth L, O'Donohue T, Chen Z, Trippett TM, Klein E, Kernan NA, Kobos R, Prockop SE, Scaradavou A, Shukla N, Steinherz PG, Moskowitz AJ, Moskowitz CH, Boulad F (2018) Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 59(8):1861\u20131870. https:\/\/doi.org\/10.1080\/10428194.2017.1403601","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3812_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Br\u00f6ckelmann","year":"2017","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Casasnovas O, Hutchings M, von Tresckow B, J\u00fcrgens M, McCall S, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A (2017) Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 28(6):1352\u20131358. https:\/\/doi.org\/10.1093\/annonc\/mdx072","journal-title":"Ann Oncol"},{"issue":"5","key":"3812_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","volume":"95","author":"HJ Adams","year":"2016","unstructured":"Adams HJ, Kwee TC (2016) Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol 95(5):695\u2013706. https:\/\/doi.org\/10.1007\/s00277-016-2619-9","journal-title":"Ann Hematol"},{"issue":"11","key":"3812_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00277-011-1209-0","volume":"90","author":"GT Sucak","year":"2011","unstructured":"Sucak GT, \u00d6zkurt ZN, Suyani E, Ya\u015far DG, Akdemir \u00d6\u00dc, Aki Z, Ye\u011fin ZA, Ya\u011fci M, Kapucu \u00d6L (2011) Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol 90(11):1329\u20131336. https:\/\/doi.org\/10.1007\/s00277-011-1209-0","journal-title":"Ann Hematol"},{"issue":"11","key":"3812_CR16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","volume":"17","author":"JP Smeltzer","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, Dipersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA (2011) Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 17(11):1646\u20131652. https:\/\/doi.org\/10.1016\/j.bbmt.2011.04.011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3812_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbmt.2017.09.006","volume":"24","author":"V Proch\u00e1zka","year":"2018","unstructured":"Proch\u00e1zka V, Gawande RS, Cayci Z, Froelich JW, Cao Q, Wilke C, Dusenbery K, Weisdorf DJ, Bachanova V (2018) Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 24(1):64\u201370. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3812_CR18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21(6):1046\u20131053. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3812_CR19","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","volume":"24","author":"J Olivieri","year":"2018","unstructured":"Olivieri J, Mosna F, Pelosini M et al (2018) A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant 24(9):1814\u20131822. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3812_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","volume":"13","author":"BM William","year":"2013","unstructured":"William BM, Loberiza FR Jr, Whalen V et al (2013) Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 13(4):417\u2013423. https:\/\/doi.org\/10.1016\/j.clml.2013.03.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"3812_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.clml.2018.02.008","volume":"18","author":"S Grisariu","year":"2018","unstructured":"Grisariu S, Shapira MY, Or R et al (2018 Apr) Thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma. Clin Lymphoma Myeloma Leuk 18(4):272\u2013279. https:\/\/doi.org\/10.1016\/j.clml.2018.02.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"3812_CR22","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.bbmt.2018.02.020","volume":"24","author":"Y Nieto","year":"2018","unstructured":"Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS (2018) Phase II trial of high-dose gemcitabine\/busulfan\/melphalan with autologous stem cell transplantation for primary refractory or poor-risk relapsed Hodgkin lymphoma. Biol Blood Marrow Transplant 24(8):1602\u20131609. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"3812_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/cncr.30482","volume":"123","author":"SA Milgrom","year":"2017","unstructured":"Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD (2017) A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 123(8):1363\u20131371. https:\/\/doi.org\/10.1002\/cncr.30482","journal-title":"Cancer."},{"key":"3812_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","volume":"81","author":"S Kahn","year":"2011","unstructured":"Kahn S, Flowers C, Xu Z et al (2011) Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 81:175\u2013180. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.05.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3812_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.radonc.2011.12.031","volume":"103","author":"T Biswas","year":"2012","unstructured":"Biswas T, Culakova E, Friedberg JW, Kelly JL, Dhakal S, Liesveld J, Phillips GL, Constine LS (2012) Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol 103:367\u2013372. https:\/\/doi.org\/10.1016\/j.radonc.2011.12.031","journal-title":"Radiother Oncol"},{"issue":"1","key":"3812_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","volume":"17","author":"M Levis","year":"2017","unstructured":"Levis M, Piva C, Filippi AR et al (2017) Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin\u2019s lymphoma with incomplete response before autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk 17(1):14\u201322. https:\/\/doi.org\/10.1016\/j.clml.2016.09.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"3812_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/annonc\/mdh304","volume":"15","author":"J Czyz","year":"2004","unstructured":"Czyz J, Dziadziuszko R, Knopinska-Postuszuy W et al (2004) Outcome and prognostic factors in advanced Hodgkin\u2019s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 15(8):1222\u20131230","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03812-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03812-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03812-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:21:49Z","timestamp":1611361309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03812-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03812-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"19 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}